Inozyme Other Stockholder Equity vs Net Debt Analysis

INZY Stock

USD 4.44 0.11 2.54%

Inozyme PharmaInc financial indicator trend analysis is infinitely more than just investigating Inozyme PharmaInc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inozyme PharmaInc is a good investment. Please check the relationship between Inozyme PharmaInc Other Stockholder Equity and its Net Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme PharmaInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme PharmaInc guide.

Other Stockholder Equity vs Net Debt

Other Stockholder Equity vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inozyme PharmaInc Other Stockholder Equity account and Net Debt. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Inozyme PharmaInc's Other Stockholder Equity and Net Debt is 0.41. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Net Debt in the same time period over historical financial statements of Inozyme PharmaInc, assuming nothing else is changed. The correlation between historical values of Inozyme PharmaInc's Other Stockholder Equity and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Inozyme PharmaInc are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Other Stockholder Equity i.e., Inozyme PharmaInc's Other Stockholder Equity and Net Debt go up and down completely randomly.

Correlation Coefficient

0.41

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Other Stockholder Equity

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Inozyme PharmaInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inozyme PharmaInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme PharmaInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme PharmaInc guide.Enterprise Value is likely to rise to about 241.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 19.8 K in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	211K	1.9M	4.1M	4.3M
Net Interest Income	211K	1.9M	4.1M	4.3M

Interest Income Net Interest Income

Inozyme PharmaInc fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Net Invested Capital	Total Current Assets	Net Working Capital
Total Assets		0.97	0.95	0.98	0.97	0.85	-0.05	-0.88	0.74	0.42	0.8	0.85	0.78	1.0	0.78	0.87	1.0	-0.73	0.94	0.9	0.83	-0.63	0.87	0.99	1.0	1.0
Other Current Liab	0.97		0.96	0.93	0.92	0.88	0.16	-0.93	0.64	0.19	0.68	0.81	0.62	0.96	0.79	0.92	0.98	-0.67	0.94	0.92	0.85	-0.56	0.89	0.96	0.98	0.97
Total Current Liabilities	0.95	0.96		0.95	0.94	0.94	0.12	-0.93	0.75	0.2	0.73	0.9	0.63	0.94	0.71	0.89	0.95	-0.78	0.96	0.88	0.87	-0.68	0.88	0.95	0.95	0.94
Total Stockholder Equity	0.98	0.93	0.95		1.0	0.91	-0.16	-0.83	0.85	0.48	0.88	0.93	0.83	0.97	0.67	0.77	0.97	-0.86	0.93	0.84	0.77	-0.79	0.82	0.99	0.96	0.96
Net Tangible Assets	0.97	0.92	0.94	1.0		0.91	-0.18	-0.81	0.86	0.49	0.89	0.93	0.83	0.97	0.63	0.76	0.97	-0.87	0.91	0.82	0.75	-0.79	0.82	0.99	0.96	0.95
Property Plant And Equipment Net	0.85	0.88	0.94	0.91	0.91		0.03	-0.81	0.86	0.2	0.77	0.96	0.64	0.84	0.53	0.69	0.86	-0.9	0.89	0.78	0.73	-0.83	0.81	0.88	0.84	0.83
Net Debt	-0.05	0.16	0.12	-0.16	-0.18	0.03		-0.38	-0.42	-0.88	-0.54	-0.19	-0.61	-0.06	0.32	0.33	-0.03	0.29	0.17	0.28	0.41	0.35	0.02	-0.08	0.0	-0.01
Retained Earnings	-0.88	-0.93	-0.93	-0.83	-0.81	-0.81	-0.38		-0.57	-0.03	-0.55	-0.74	-0.48	-0.88	-0.89	-0.93	-0.89	0.6	-0.97	-0.97	-0.98	0.49	-0.8	-0.86	-0.9	-0.89
Accounts Payable	0.74	0.64	0.75	0.85	0.86	0.86	-0.42	-0.57		0.6	0.95	0.96	0.86	0.73	0.35	0.42	0.73	-0.96	0.74	0.58	0.5	-0.95	0.64	0.78	0.7	0.69
Cash	0.42	0.19	0.2	0.48	0.49	0.2	-0.88	-0.03	0.6		0.77	0.42	0.87	0.43	0.15	0.03	0.39	-0.46	0.23	0.16	0.0	-0.49	0.26	0.42	0.37	0.39
Non Current Assets Total	0.8	0.68	0.73	0.88	0.89	0.77	-0.54	-0.55	0.95	0.77		0.89	0.97	0.8	0.45	0.45	0.79	-0.88	0.73	0.61	0.48	-0.86	0.68	0.83	0.77	0.77
Non Currrent Assets Other	0.85	0.81	0.9	0.93	0.93	0.96	-0.19	-0.74	0.96	0.42	0.89		0.78	0.84	0.48	0.63	0.85	-0.95	0.86	0.72	0.67	-0.9	0.77	0.88	0.83	0.81
Other Assets	0.78	0.62	0.63	0.83	0.83	0.64	-0.61	-0.48	0.86	0.87	0.97	0.78		0.78	0.49	0.42	0.76	-0.76	0.66	0.58	0.42	-0.74	0.63	0.79	0.74	0.75
Cash And Short Term Investments	1.0	0.96	0.94	0.97	0.97	0.84	-0.06	-0.88	0.73	0.43	0.8	0.84	0.78		0.79	0.87	1.0	-0.72	0.94	0.9	0.82	-0.62	0.87	0.99	1.0	1.0
Net Receivables	0.78	0.79	0.71	0.67	0.63	0.53	0.32	-0.89	0.35	0.15	0.45	0.48	0.49	0.79		0.84	0.78	-0.33	0.84	0.94	0.87	-0.23	0.69	0.72	0.8	0.81
Common Stock Shares Outstanding	0.87	0.92	0.89	0.77	0.76	0.69	0.33	-0.93	0.42	0.03	0.45	0.63	0.42	0.87	0.84		0.88	-0.42	0.87	0.87	0.88	-0.28	0.85	0.83	0.9	0.89
Short Term Investments	1.0	0.98	0.95	0.97	0.97	0.86	-0.03	-0.89	0.73	0.39	0.79	0.85	0.76	1.0	0.78	0.88		-0.73	0.94	0.9	0.82	-0.63	0.89	0.99	1.0	1.0
Non Current Liabilities Total	-0.73	-0.67	-0.78	-0.86	-0.87	-0.9	0.29	0.6	-0.96	-0.46	-0.88	-0.95	-0.76	-0.72	-0.33	-0.42	-0.73		-0.76	-0.6	-0.57	0.99	-0.56	-0.8	-0.7	-0.69
Capital Surpluse	0.94	0.94	0.96	0.93	0.91	0.89	0.17	-0.97	0.74	0.23	0.73	0.86	0.66	0.94	0.84	0.87	0.94	-0.76		0.97	0.94	-0.67	0.82	0.94	0.94	0.94
Other Current Assets	0.9	0.92	0.88	0.84	0.82	0.78	0.28	-0.97	0.58	0.16	0.61	0.72	0.58	0.9	0.94	0.87	0.9	-0.6	0.97		0.95	-0.51	0.77	0.88	0.91	0.91
Other Stockholder Equity	0.83	0.85	0.87	0.77	0.75	0.73	0.41	-0.98	0.5	0.0	0.48	0.67	0.42	0.82	0.87	0.88	0.82	-0.57	0.94	0.95		-0.47	0.66	0.81	0.84	0.84
Total Liab	-0.63	-0.56	-0.68	-0.79	-0.79	-0.83	0.35	0.49	-0.95	-0.49	-0.86	-0.9	-0.74	-0.62	-0.23	-0.28	-0.63	0.99	-0.67	-0.51	-0.47		-0.44	-0.71	-0.6	-0.59
Deferred Long Term Liab	0.87	0.89	0.88	0.82	0.82	0.81	0.02	-0.8	0.64	0.26	0.68	0.77	0.63	0.87	0.69	0.85	0.89	-0.56	0.82	0.77	0.66	-0.44		0.84	0.87	0.87
Net Invested Capital	0.99	0.96	0.95	0.99	0.99	0.88	-0.08	-0.86	0.78	0.42	0.83	0.88	0.79	0.99	0.72	0.83	0.99	-0.8	0.94	0.88	0.81	-0.71	0.84		0.99	0.99
Total Current Assets	1.0	0.98	0.95	0.96	0.96	0.84	0.0	-0.9	0.7	0.37	0.77	0.83	0.74	1.0	0.8	0.9	1.0	-0.7	0.94	0.91	0.84	-0.6	0.87	0.99		1.0
Net Working Capital	1.0	0.97	0.94	0.96	0.95	0.83	-0.01	-0.89	0.69	0.39	0.77	0.81	0.75	1.0	0.81	0.89	1.0	-0.69	0.94	0.91	0.84	-0.59	0.87	0.99	1.0

Click cells to compare fundamentals

Inozyme PharmaInc Account Relationship Matchups

Inozyme PharmaInc fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	47.9M	169.4M	123.5M	139.2M	200.8M	132.8M
Other Current Liab	2.3M	6.9M	8.5M	7.5M	12.6M	7.2M
Total Current Liabilities	3.2M	10.0M	11.6M	14.7M	14.7M	10.4M
Total Stockholder Equity	(33.2M)	158.1M	109.3M	118.6M	140.5M	87.9M
Net Tangible Assets	(33.2M)	158.1M	109.3M	118.4M	136.2M	74.5M
Property Plant And Equipment Net	298K	2.6M	4.4M	3.6M	2.6M	2.5M
Net Debt	(31.6M)	(158.6M)	(19.9M)	(26.1M)	12.0M	12.6M
Retained Earnings	(34.7M)	(91.1M)	(147.7M)	(214.8M)	(285.9M)	(271.6M)
Accounts Payable	901K	3.1M	2.4M	2.5M	1.2M	2.0M
Cash	31.6M	159.9M	23.3M	32.9M	34.6M	42.4M
Non Current Assets Total	484K	18.4M	8.2M	7.8M	4.6M	7.3M
Non Currrent Assets Other	56K	3.5M	3.4M	3.8M	1.7M	2.3M
Cash And Short Term Investments	47.1M	159.9M	111.8M	127.9M	188.6M	124.4M
Net Receivables	104K	155K	62K	115K	385K	404.3K
Common Stock Shares Outstanding	23.4M	23.4M	23.6M	37.8M	51.8M	32.1M
Short Term Investments	15.5M	119.7M	88.5M	95.0M	154.0M	88.0M
Liabilities And Stockholders Equity	47.9M	169.4M	123.5M	139.4M	200.8M	132.8M
Non Current Liabilities Total	77.9M	1.3M	2.6M	6.1M	45.7M	25.2M
Capital Surpluse	1.4M	249.2M	256.9M	333.4M	383.4M	402.5M
Other Current Assets	224K	3.3M	3.5M	3.5M	7.3M	7.6M
Other Stockholder Equity	(76.5M)	79.8M	133.4M	333.6M	426.4M	447.7M
Total Liab	81.2M	11.3M	14.3M	20.8M	60.4M	32.7M
Net Invested Capital	(33.2M)	158.1M	109.3M	122.5M	185.2M	96.8M
Total Current Assets	47.5M	151.0M	115.3M	131.4M	196.3M	125.5M
Accumulated Other Comprehensive Income	5K	2K	18K	(205K)	41K	43.1K
Net Working Capital	44.2M	141.0M	103.7M	116.7M	181.6M	115.1M
Property Plant Equipment	298K	2.6M	4.4M	2.0M	2.3M	2.1M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inozyme PharmaInc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inozyme PharmaInc's short interest history, or implied volatility extrapolated from Inozyme PharmaInc options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Inozyme PharmaInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inozyme PharmaInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inozyme Pharmainc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inozyme Pharmainc Stock:

How To Invest In Inozyme

Details

Is Inozyme Stock a good investment?

Details

What is Inozyme PharmaInc's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme PharmaInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme PharmaInc guide.

Note that the Inozyme PharmaInc information on this page should be used as a complementary analysis to other Inozyme PharmaInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Inozyme Stock analysis

When running Inozyme PharmaInc's price analysis, check to measure Inozyme PharmaInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme PharmaInc is operating at the current time. Most of Inozyme PharmaInc's value examination focuses on studying past and present price action to predict the probability of Inozyme PharmaInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme PharmaInc's price. Additionally, you may evaluate how the addition of Inozyme PharmaInc to your portfolios can decrease your overall portfolio volatility.

	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Stocks Directory Find actively traded stocks across global markets

Is Inozyme PharmaInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inozyme PharmaInc. If investors know Inozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inozyme PharmaInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.37)

Return On Assets

(0.28)

Return On Equity

(0.55)

The market value of Inozyme PharmaInc is measured differently than its book value, which is the value of Inozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Inozyme PharmaInc's value that differs from its market value or its book value, called intrinsic value, which is Inozyme PharmaInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inozyme PharmaInc's market value can be influenced by many factors that don't directly affect Inozyme PharmaInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Inozyme PharmaInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inozyme PharmaInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inozyme PharmaInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inozyme Other Stockholder Equity vs Net Debt Analysis

Other Stockholder Equity vs Net Debt

Other Stockholder Equity vs Net Debt Correlation Analysis

Correlation Coefficient

Other Stockholder Equity

Net Debt

Inozyme PharmaInc fundamental ratios Correlations

Inozyme PharmaInc Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inozyme PharmaInc fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Inozyme Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Short Term Investments	+ 1.0	Cash And Short Term Investments

Other Stockholder Equity	- 0.98	Retained Earnings
Other Current Assets	- 0.97	Retained Earnings
Capital Surpluse	- 0.97	Retained Earnings
Non Current Liabilities Total	- 0.96	Accounts Payable
Non Current Liabilities Total	- 0.95	Non Currrent Assets Other
Total Liab	- 0.95	Accounts Payable